Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2095 articles with Gilead Sciences, Inc.
-
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
7/28/2022
Gilead Sciences, Inc. announced results reinforcing Biktarvy® as a highly efficacious treatment option for a broad range of people with HIV, including individuals with HIV/hepatitis B coinfection.
-
City of Hope revealed that the oldest person living with HIV has achieved clinical remission after undergoing stem cell transplantation at the center more than three years ago.
-
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
7/22/2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Commission (EC) adopted a positive opinion on the fulfillment of the last specific obligation and recommended the granting of Marketing Authorization (MA) for Veklury® (remdesivir) that is no longer subject to specific obligations.
-
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
7/21/2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 24th International AIDS Conference (AIDS 2022).
-
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
7/20/2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced an $85 million contribution to the Gilead Foundation to further the company's vision of creating a healthier world for all people.
-
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
7/19/2022
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury ® (Remdesivir).
-
Kyowa Kirin announced it is dropping its Parkinson’s disease candidate, KW-6356, a follow-up to Nourianz, despite promising Phase II data that showed the drug is "potentially effective."
-
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
7/12/2022
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Deborah Telman will join the company as Executive Vice President, Corporate Affairs and General Counsel, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day.
-
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
7/12/2022
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2022 financial results will be released on Tuesday, August 2, after the market closes.
-
Companies are still developing and refining treatments and preventions for COVID-19, but not all of them are approved or authorized. Here’s a look at the latest COVID-19 news.
-
After the spring reductions in the workforce that left thousands of biotech employees searching for jobs, larger companies are, for the most part, moving forward.
-
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
6/27/2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection.
-
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
6/24/2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for investigational lenacapavir for the treatment of HIV-1 infection.
-
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
6/23/2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 48 results from the Pivotal Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex® (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection.
-
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
6/21/2022
Two Oral Presentations and 22 Posters Will Be Presented Across HDV, HCV, HBV, NASH and PSC.
-
It was an extraordinarily busy week for clinical trial news and updates due to several prominent international conferences. Here’s a look at some of the highlights.
-
Real World Study Demonstrates Consistent Survival for Gilead’s Yescarta Across Race/Ethnicity
6/6/2022
The study revealed that Yescarta was both safe and effective in adult patients regardless of race and ethnicity. -
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
6/6/2022
Gilead Sciences, Inc. (Nasdaq: GILD) today presented final data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies, at least one of them for metastatic disease.
-
Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology's annual meeting.
-
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
6/4/2022
Everest Medicines announces that its licensing partner, Gilead Sciences, Inc., reported positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy® versus physicians' choice of chemotherapy in heavily pre-treated HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.